Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dual specificity phosphatase 9 (DUSP9), also known as MKP-4, is a member of the dual specificity phosphatase family that catalyzes the removal of phosphate groups from both phosphotyrosine and phosphoserine/threonine residues on protein substrates. DUSP9 plays a crucial role in the inactivation of mitogen-activated protein kinases (MAPKs), particularly the ERK, JNK, and p38 families, thus acting as a key negative regulator of MAPK signal transduction. It is expressed in various tissues, localizes predominantly in the cytoplasm, and helps fine-tune cell responses to stress, growth factors, and cytokines, being implicated in the regulation of insulin signaling, cancer cell resistance, and inflammation.
Drugs or molecules that increase DUSP9 (MKP-4) activity can dephosphorylate and inactivate MAP kinases (ERK, JNK, p38), thereby negatively regulating pro-inflammatory and stress signaling cascades and potentially reversing insulin resistance
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dual specificity phosphatase 9 (DUSP9).